Adicet Bio, Inc.
Adicet Bio
200 Constitution Drive
Menlo Park
California
94025
United States
Website: http://www.adicetbio.com/
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
26 articles with Adicet Bio, Inc.
-
Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer
10/26/2020
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Don Healey, Ph.D., as Chief Technology Officer.
-
Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell TherapyPhase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin’s lymphoma
10/22/2020
Adicet Bio, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for ADI-001, an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20 for treatment of non-Hodgkin’s lymphoma.
-
Adicet Bio to Present at the Jefferies Cell Therapy Summit
10/1/2020
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer of Adicet Bio, and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer of Adicet Bio, will participate in a fireside chat at the Jefferies Cell Therapy Summit on Monday, October 5, 2020 at 2:30 PM ET.
-
Adicet Bio, Inc. Determines Not to Proceed with Public Offering of Common Stock - Sep 23, 2020
9/23/2020
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that it has determined not to proceed with its proposed public offering of 4,500,000 shares of its common stock previously announced on September 21, 2020.
-
Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock - Sep 21, 2020
9/21/2020
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock.
-
Adicet Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
9/18/2020
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that on September 17, 2020,
-
Adicet Bio Appoints Nick Harvey as Chief Financial Officer
9/16/2020
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Nick Harvey as Chief Financial Officer.
-
Adicet Bio to Present at the Cantor Virtual Global Healthcare Conference
9/15/2020
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer of Adicet Bio, will present at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 8:40 AM ET. A live audio webcast of the presentation can be accessed on the Investors section of Ad
-
Adicet Announces Completion of Merger with resTORbio
9/15/2020
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc. (previously trading on Nasdaq under the symbol “TORC”)
-
Adicet Bio Receives $10 Million Product Development Milestone From Regeneron
8/5/2020
Adicet Bio, Inc., a privately-held biopharmaceutical company, announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the terms of its strategic collaboration with Regeneron.
-
The deal is expected to close in the second half of 2020. Once finalized, the combined company will run under the name Adicet Bio and is expected to trade on the Nasdaq Global Market under a new ticker symbol, which hasn’t been announced yet.
-
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
4/29/2020
Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20 for treatment of non-Hodgkin’s lymphoma
-
Adicet Bio to Present at J.P. Morgan Healthcare Conference
1/9/2020
Adicet Bio, Inc., a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced today that the company will present at the 38th Annual J.P. Morgan Healthcare Conference.
-
Adicet Bio Raises $80M in Series B Financing
10/2/2019
As part of the Series B financing, aMoon and JJDC will be joining Adicet's Board of Directors.
-
Adicet Bio Appoints Francesco Galimi, M.D., Ph.D., SVP and Chief Medical Officer
9/23/2019
Adicet Bio, Inc., a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced today the appointment of Francesco Galimi, M.D., Ph.D., as Senior Vice President and Chief Medical Officer.
-
Adicet Bio Appoints Anil Singhal Chief Executive Officer
4/30/2019
Adicet Bio, Inc. announced that the Board of Directors has appointed Anil Singhal, Ph.D., MBA, President and Chief Executive Officer, effective May 6, 2019.
-
Adicet Bio to Present at the 37th J.P. Morgan Healthcare Conference on January 9
1/7/2019
Adicet Bio, Inc. announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference.
-
Adicet Bio appoints Stewart Abbot, Ph.D. as Chief Scientific Officer
6/27/2018
Dr. Abbot brings extensive industry experience in the research, early product development and clinical translation of cell-based therapies.
-
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
4/30/2018
Adicet Bio, Inc. announced that it has appointed Elizabeth "E.J." Read, M.D. as its Chief Technology Officer. Dr. Read brings extensive industry experience in the successful development of cell-based biological therapies.
-
Adicet Bio Announces the Transition of Founder, President and Chief Executive Officer Dr. Aya Jakobovits
3/6/2018
Adicet Bio, Inc. ("Adicet"), a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced today that Aya Jakobovits, Ph.D., Founder of Adicet Bio, has retired from her position as President and Chief Executive Officer.